XClinical’s review of 2010
XClinical GmbH, Munich, Germany – February 15th, 2011 – XClinical, European vendor of innovative software products for eClinical trials, well known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, had a very successful and innovative business year.
Constant growth in the past years and the successful market relaunch of the STUDY COMPOSER as a standalone software tool at the beginning of 2010 has allowed XClinical to adapt its staffing situation to the favourable conditions and thus six new colleagues joined the corporate workforce. “The enlarged team enables us to develop our products more target-oriented and to support our customers even more comprehensively,” comments Dr. Philippe Verplancke, CEO and QM at XClinical. The changes within XClinical were also made visible to the outside: Marketing Department renewed the Corporate Design including the relaunch of the company website and existing marketing materials, reworked the company’s concept for conference appearance and implemented an official newsletter.
Despite - or even because of - the efforts of integrating new staff into an existing team and existing workflows, XClinical experienced continuous growth and was able to expand its existing markets in the US, Europe and Asia. Both new and existing clients started about 45 new projects in 2011. To a large extend, this is owed to the company’s frequent participation in international pharmaceutical and data management events to establish contact with the industry worldwide. “It’s not only that we attend those conferences as exhibitors and speakers. Last year we also hosted the 2nd XClinical End-to-End Workshop. In our opinion, being a software provider also means sharing previous experience.” says Dr. Verplancke. “And it also means providing a platform for our clients to share their experience and to enter into dialogue with us. Last year we hosted the 6th XClinical User Meeting, which again was extremely successful.”
Affirmation of work by FDA’s future development plans
Last year XClinical received affirmation of its work by the FDA (Federal Drug Association). In the second half of 2010 the FDA announced to intensify the development of a data standard for electronic submission. XClinical experts see their opinion reconfirmed by the FDA’s approach to use CDISC standards for e-submission in the foreseeable future. “The FDA’s plan to reconsider the CDISC ODM standard in particular for e-submission really validates our approach. Our EDC System MARVIN and our eCRF design tool STUDY COMPOSER are both CDISC-compliant,” claims the CEO of XClinical.
In 2011, XClinical aims at maintaining last year’s success. With the planned recruitment of more new employees, particularly in the software development department, XClinical strives to meet market requirements, develop new products and refine existing ones.
Motivated by last year’s workshop success, XClinical is planning to host a workshop specially designed for CEOs of contract research organizations and will also reissue the End-To-End workshop. ”Having dedicated this much energy to the restructuring and expansion of our team, we have built the foundations for the expansion of last year’s success”, says Dr. Verplancke.
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries.
XClinical develops and markets MARVIN, a CDISC ODM-certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM).
Phone: +49 (0)89 / 45 22 77 – 5220
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release XClinical’s review of 2010 here
News-ID: 162591 • Views: 2747
More Releases from XClinical GmbH
XClinical integrates INCA, Medical Coding software, with its EDC system MARVIN
XClinical releases version 1.6. of its coding system INCA XClinical GmbH, Munich, Germany, May 8, 2014 – XClinical, a global provider of eClinical solutions, today announces the availability of INCA version 1.6, medical coding software featuring MedDRA and WHODrug dictionaries, including an automated web interface to EDC systems such as MARVIN. INCA (“Integrated Coding Architecture”) is a web-based application that enables users to classify health related data such as patient medications and
XClinical CRO Executive Forum
XClinical hosts its first CRO Executive Forum on May 10, 2011 in Aying, Germany. XClinical GmbH, Munich, Germany – April 14, 2011 – XClinical, a European vendor of innovative software products for eClinical trials known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, hosts its first CRO Executive Forum especially designed for CEOs of CROs on May 10, 2011 in Aying, Germany. The concept In 2010, XClinical started to provide
XClinical’s “MARVIN4KIDS” at the DIA Geneva
XClinical presents the initiative “MARVIN4KIDS” at the DIA Annual EuroMeeting in Geneva XClinical GmbH, Munich, Germany – March 25, 2011 – XClinical, a European vendor of innovative software products for eClinical trials known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, presents the initiative “MARVIN4KIDS” for the first time at the DIA Annual EuroMeeting in Geneva. The conference takes place from March 28 to 30. “MARVIN4KIDS” MARVIN4KIDS is an XClinical
XClinical and IDDI: The best of 2 worlds
The IWR/IVR system ID-netTM developed by IDDI now provides an interface to MARVIN, XClinical’s EDC system XClinical GmbH, Munich, Germany – March 25, 2011 – XClinical, a European vendor of innovative software products for eClinical trials known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, presents the web-based open interface of IDDI’s ID-netTM to XClinical’s EDC system MARVIN at the DIA Annual EuroMeeting in Geneva. About ID-netTM ID-netTM
More Releases for Clinical
Clinical Laboratory Market in Indonesia, Clinical Laboratory Industry in Indones …
"Increase in healthcare expenditure from the Indonesian government has driven the growth of clinical laboratory market in Indonesia." Increase in Healthcare Awareness: Largely driven by increase in healthcare spending by aging population (~$ 260 per person by 2050), rising income levels, rising awareness for preventive testing, advanced healthcare diagnostic tests offerings, and central government's healthcare measures. Developments in Testing and Preference for Evidence based testing: There is also a rising number
Are you spending more time with yellow files than with patients? Healthbridge can change that with our intuitive and easy to use clinical platform that is designed specifically for the medical practitioner at the practice. smaller2 Easily access patient information Cloud-based technology enables you to store rich clinical information that can be easily accessed as and when you need it. Medical billing software innovation Become a paperless practice Create scripts, sick notes, and clinical notes electronically. Plus, have
Clinical Research and Clinical Trials Summit
Clinical Research 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation. This is the premier interdisciplinary forum for
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
According to a recent market report published by Persistence Market Research titled “Clinical Communication and Collaboration Market: Global Industry Analysis (2012–2016) and Forecast (2017–2025),” revenue from the global clinical communication and collaboration market was US$ 138.5 Mn in 2012 and US$ 214.8 Mn in 2016, representing a CAGR of 11.6% from 2012 to 2016. This revenue growth is attributed to addition of new features in clinical communication and collaboration solutions.
E-Clinical Trial Solutions Market To Accelerating Clinical Development Technolog …
The study of the "Global e-Clinical Trial Solutions Market" provides the market size information and market trends along with the factors and parameters impacting it in both short and long term. The study ensures a 360° view, bringing out the complete key insights of the industry. The Global e-Clinical Trial Solutions Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the e-Clinical